Topical Nasal Composition Combining Antibiotic and Immunomodulation for CRS
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chronic Rhinosinusitis (CRS) lacks an effective and definitive treatment due to its complex, multi-causal nature involving epithelial barrier damage, microbial infections, and inflammatory responses, leading to persistent inflammation and variable treatment outcomes.
Innovation Solution
A topical nasal pharmaceutical composition comprising Rifamycin, Fluticasone, Oxymetazoline, and lyophilized bacterial antigens, which provides antibacterial, anti-inflammatory, and immunomodulatory effects to address the underlying causes of CRS.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional single-agent or simple combination therapies are used for CRS, then treatment simplicity is maintained, but therapeutic efficacy is insufficient due to the complex multi-causal etiology of CRS
Solution Approach 1:
The patent combines four distinct active ingredients (Rifamycin, Fluticasone, Oxymetazoline, and Lyophilized Bacterial Antigens) into a single nasal spray formulation. This merging of multiple therapeutic agents addresses the multi-causal nature of CRS by simultaneously targeting bacterial infection, inflammation, congestion, and immune response, thereby resolving the contradiction between treatment simplicity and therapeutic efficacy.
Solution Approach 2:
The formulation creates a composite pharmaceutical composition where each ingredient contributes a different therapeutic mechanism. Rifamycin provides antibacterial action, Fluticasone provides anti-inflammatory action, Oxymetazoline provides decongestant action, and Lyophilized Bacterial Antigens provide immunomodulatory action. This composite approach allows the single formulation to address multiple etiological factors of CRS simultaneously.
2Reliability
If multiple active ingredients are combined to address CRS etiology, then therapeutic efficacy is improved, but formulation complexity increases
Solution Approach 1:
The patent merges four complex therapeutic agents into a single unified nasal spray formulation. This consolidation simplifies the treatment regimen for patients while maintaining the multifaceted therapeutic approach needed to address the complex etiology of CRS, effectively resolving the contradiction between improved efficacy through multiple ingredients and the complexity of formulation.
3Reliability
If topical nasal composition is applied, then local therapeutic effect is achieved, but systemic side effects may occur
Solution Approach 1:
The patent employs a topical nasal spray formulation that delivers therapeutic agents directly to the site of CRS pathology in the nasal passages and sinuses. This localized delivery ensures high concentration of medications at the target site while minimizing systemic absorption and associated side effects, thereby resolving the contradiction between achieving strong local therapeutic effect and avoiding systemic harmful factors.
Data Source
AI summary
The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.